Overview

AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib

Status:
Completed

Trial end date:
2019-06-25

Target enrollment:

Participant gender:

Summary

This phase 2 study is an open-label, multi-center study to determine the safety and tolerability of AMG 386 in combination with sunitinib in the treatment of subjects with metastatic renal cell carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen

Treatments:

Angiogenesis Inhibitors
Sunitinib
Trebananib